Dr. Seet has a proven track record as an entrepreneur doing business in China with a focus on strategic and change management, and has provided consultancy to evaluate investment opportunities related to medical devices, pharmaceuticals and healthcare. Prior to joining LehmanBush, he was a Director of DM Capital, located in Shenzhen, and focused on China-based healthcare, medical device, new media and educational investment opportunities. He is also actively involved in social entrepreneurship and education and training.

Dr. Seet served as the Chief Medical Officer of the Singapore Armed Forces Medical Corps. In 1984 he became the Asia Regional Director for Medical and Regulatory Affairs, and Regional Director of Corporate Affairs for Ciba-Geigy (now part of Novartis). He subsequently was appointed Vice-President, SmithKline Beecham International and General Manager of Tianjin SmithKline & French Labs based in Tianjin. He also served as the Greater China Managing Director for Glaxo Smith Kline China. He was previously an Executive Director of Longlife Group Holdings Ltd, a company listed on the GEM board of the Hong Kong Stock Exchange, a Non-executive Chairman, Rockeby Biomed Ltd, a company listed on the Australian Stock Exchange, and an Independent Non-Executive Director of Jiwa Bio-Pharm Holdings Ltd, a company listed on the main board of the Hong Kong Stock Exchange.

Dr. Seet also served as an Associate Professor in Entrepreneurship and Strategic Management at Nanyang Business School, Deputy Director of the Nanyang Technopreneurship Center (NTC) at which he established the Minor in Entrepreneurship program, and Managing Director of NTU Ventures Pte Ltd, the wholly-owned investment holding company of NTU. He also established and was the Founding Director of the highly successful Executive MBA program jointly organized with Shanghai Jiaotong University. Dr. Seet speaks English, Chinese, and Malay, and earned a medical degree from the National University of Singapore.